Aim: The action of oestrogen has traditionally been attributed to the activation of nuclear receptors (ERα and ERβ). A third receptor, the G protein-coupled oestrogen receptor (GPER), has been described as mediator of the rapid action of oestrogen. Based on the possible protective role of oestrogen in the cardiovascular system, the present study was designed to determine whether selective GPER activation induces relaxation of mesenteric resistance arteries in both sexes and which signalling pathways are involved. Main methods: Third-order mesenteric arteries were isolated, and concentration-response curves were plotted following the cumulative addition of the selective GPER agonist G-1 (1 nM − 10 μM) following induction of contraction with phenylephrine (3 μM). The vasodilatory effects of G-1 were assessed before and after removal of the endothelium or incubation for 30 min with nitric oxide synthase (N ω -nitro-L-arginine methyl ester -L-NAME, 300 μM) and cyclooxygenase (indomethacin -INDO, 10 μM) inhibitors alone or combined, PI3K-Akt pathway inhibitor (LY-294,002, 2.5 μM) or a potassium channel blocker (tetraethylammonium -TEA, 5 mM). GPER immunolocalisation was also performed on the investigated arteries. Key findings: The tested GPER agonist induced concentration-dependent relaxation of the mesenteric resistance arteries without differences related to sex that were partially endothelium dependent, mainly mediated by the PI3K-Akt-eNOS pathway and attenuated by nonspecific potassium channel blockade. In addition, the endothelial GPER immunolocalisation was stronger among females. Significance: This evidence provides a new perspective for understanding the mechanisms involved in the vascular responses triggered by oestrogen via GPER in both sexes.
Introduction
Oestrogens (17 β-oestradiol in particular) regulate a broad scope of physiological phenomena [1] , including vascular homeostasis, through their interactions with endothelial factors [2, 3] . Within this context, the fact that the endothelium plays a crucial role in the maintenance of the vascular function through the release of powerful vasoactive factors that regulate vascular tone, such as nitric oxide (NO), endotheliumderived hyperpolarising factor (EDHF) and prostacyclin (PGI 2 ), is well established [4] . In addition, endothelium-dependent NO release might be stimulated by oestrogen through the rapid activation of phosphatidylinositol-3-kinase/protein kinase B (PI3K-Akt) and the subsequent phosphorylation of type III NO synthase (eNOS) [5, 6] . However, oestrogen also influences vascular tone through activation of potassium channels [7, 8] and direct action on vascular smooth muscle (VSM) via inhibition of the intracellular mobilisation of calcium [9, 10] . Therefore, oestrogens seem to play a relevant role in vascular function, which contributes to their cardioprotective effects in both women [11, 12] and men [13] [14] [15] .
In addition to the oestrogen receptors that mediate the classic actions (ERα and ERβ), a third receptor, the G protein-coupled oestrogen receptor (GPER), has been described as one of the factors responsible for the intracellular signalling pathway that mediates the acute (extracellular) effects of oestrogen [16, 17] . GPER is widely distributed across the cardiovascular system, which suggests that it plays a physiological role in the regulation of vascular function [18] [19] [20] [21] [22] . GPER is expressed in the endothelial and VSM cells of humans and animals of both sexes, which points to an action that is both dependent and independent of the endothelium [23] . In addition, several authors have correlated GPER activation with beneficial cardiovascular effects such as blood pressure reduction [24] , glycaemia maintenance [25] and protection against atherosclerosis [26] in animal models.
Replacement therapies using agents that offer benefits similar to those of oestrogen without its undesirable secondary effects are a source of much interest, especially with regard to their possible behaviour as protective factors against cardiovascular disease [27] [28] [29] [30] [31] [32] . Among several pharmacological agents, the selective GPER agonist G-1 is the latest to be used in experimental research on hormone replacement and is attributed an outstanding position [33, 34] . However, the role of GPER in the modulation of vascular function of resistance vessels in both sexes has not yet been fully elucidated. Therefore, the aim of the present study was to investigate the sex-based differences resulting from selective GPER activation in mesenteric resistance arteries, as well as the roles played by the endothelium, endothelial relaxing factors and potassium channels. In addition, we investigated the specific location of GPER on the vascular wall in both sexes.
Materials and methods

Animals
Adult Wistar rats (10-12 weeks old) of both sexes provided by the vivarium at the Center of Health Sciences, Federal University of Espirito Santo were used. The animals were kept in an illuminated environment (12-h light-dark cycle) under controlled temperature (22°C) and humidity (50%) with free access to water and food (standard vivarium diet, Purina Labina, São Paulo, SP -Brazil). All of the procedures complied with the biomedical research guidelines for care and use of laboratory animals, as indicated by the Brazilian Society of Science with Laboratory Animals, and were approved by the animal use ethics committee of the Federal University of Espirito Santo (031/2015).
Vaginal smear
The females' oestrus cycles were monitored through vaginal smears. Vaginal epithelial cells were collected daily between 08:00 h and 09:00 h and examined under an optical microscope following the protocol of Marcondes et al. [35] to identify the cell types present during the various phases of the oestrous cycle. The females were deemed fit for the experimental protocols when in the proestrous phase, which is characterised by high levels of ovarian hormones, to avoid any effects of variations in cycle-related hormones [36] . The males were subjected to the same daily collection procedure at similar times to reproduce the stress possibly suffered by the females.
Vascular reactivity
The rats were culled by decapitation without anaesthesia in order to prevent interference with the sustained phase of the contractile response [37] . The third-order mesenteric arteries were then identified, isolated and dissected from the adjacent non-vascular tissue. The artery segments were cut into 2-mm rings and mounted between 2 tungsten threads (40 μm in diameter) inside the chambers of a resistance myograph system (620 M; Danish Myo Technology, Aarhus, Denmark). The chambers were filled with Krebs solution (concentration given in mM): NaCl (119), KCl (4.7), KH 2 PO 4 (0.4), NaHCO 3 (14.9), MgSO 4 .7H 2 O (1.17), CaCl 2 .2H 2 O (2.5) and glucose (5.5) at 37°C and aired with carbogen (5 % CO 2 and 95 % O 2 ) as described by Mulvany & Halpern [38] . The internal circumference was normalised to 0.9⋅IC100, and the rings were gradually stretched until their internal diameters corresponded to a transmural pressure of 100 mmHg. The vesselafter being set to its working length -was challenged twice with 3 μM phenylephrine in order to elicit reproducible contractile responses. A vessel fragment simultaneously monitored for phenylephrine alone during the same time frame of the G-1 curve worked as a control for all the protocols. Endothelial viability and integrity were assessed by measuring the response of the rings previously contracted by means of phenylephrine (Phe, 3 μM) to administration of acetylcholine (ACh, 10 μM). The endothelium of the rings was rated as intact when the relaxation observed in response to ACh was ≥80 %. Following mechanical removal of the endothelium, the vessels were rated as endothelium free when the ACh-induced relaxation was b10%. Concentration-response curves were plotted for the cumulative addition of G-1 (1 nM − 10 μM; Azano Pharmaceuticals, Albuquerque, NM-USA) or vehicle (dimethyl sulphoxide -DMSO) following the previous induction of contraction with 3 μM of Phe. G-1 vasodilatory action was investigated in the presence and absence of the endothelium or the following inhibitors: N ω -nitro-L-arginine methyl ester (L-NAME, NOS inhibitor, 300
μM; Sigma, St. Louis, MO -USA), indomethacin (INDO, cyclooxygenase -COX -inhibitor, 10 μM; Sigma, St. Louis, MO -USA), a combination of L-NAME (300 μM) and INDO (10 μM), LY-294,002 (PI3K-Akt inhibitor, 2.5 μM; Sigma, St. Louis, MO -USA), tetraethylammonium (TEA, K + channel blocker, 5 mM; Sigma,St. Louis, MO -USA), G36 (specific GPER antagonist, 1 μM; Azano Pharmaceuticals, Albuquerque, NM -USA) and ICI 182,780 (ERα and ERβ antagonist, 1 μM; Sigma, St. Louis, MO -USA). The samples were incubated for 30 min before testing the G-1 concentration-response curve, and the percent relaxation was determined using a LabChart 8 data acquisition system (AD Instruments Pty Ltd., New South Wales, Australia).
Immunofluorescence
Immunolocalisation of GPER was performed according to the protocol of Aires et al. [39] with some modifications. Briefly, cold methanol-DMSO (1:1 v/v)-fixed cryosections (10 μm) of mesenteric arteries from male and female rats were fixed in cold acetone for 15 min and rinsed in PBS (1 % BSA + 0.3 % Triton X-100 in PBS). Following appropriate blocking procedures (3 % BSA + 0.3 % Triton X-100 in PBS, 30 min), the cross reactivity of the secondary antibodies with the alternating primary antibodies was removed. The slides were then incubated with rabbit anti-GPER (Santa Cruz Biotechnology, Santa Cruz, California -USA, 1:100) overnight at 4°C, followed by incubation for 1 h with a goat anti-rabbit secondary antibody conjugated to Alexa Fluor 633 (1:500, Invitrogen, Carlsbad, CA -USA). The sections were examined under a Nikon Eclipse Tifluorescence microscope with an excitation wavelength of 633 nm and an emission wavelength of 650 nm. The fluorescence intensity (measured using ImageJ® software 1.42q; Wayne Rasband, NIH) of the vessels was expressed as the relative fluorescence intensity (arbitrary units), and 8 fields per each slide containing the endothelial layer plus 8 fields per each slide containing the smooth muscle layer were measured.
Statistical analysis
The data are expressed as the mean ± standard error of the mean (SEM), and the statistical analysis was performed using GraphPad Prism 6 (GraphPad Software, La Jolla, CA -USA). The vasodilator response to G-1 was assessed by means of two-way analysis of variance (ANOVA) followed by the Bonferroni post-hoc test. Data were considered to be statistically significant when p b 0.05.
Results
Vascular reactivity in response to G-1
The influence of sex on the GPER-mediated vascular response was assessed using isolated artery segments. The tested GPER agonist [G-1 (1 nM − 10 μM)] induced concentration-dependent relaxation of the mesenteric resistance arteries in both females (77.3 ± 2.0 %) and males (78.2 ± 2.6 %), without any differences as a function of sex (Fig.  1) . To investigate the participation of the endothelium in G-1-induced relaxation in both groups, the arterial endothelium was removed. Under this condition, the response to G-1 was decreased in both females (43.1 ± 3.0 %) and males (63.3 ± 4.9 %). This negative effect was more accentuated among the females (Fig. 1) , as they exhibited more than double the reduction of relaxation compared with the males (44.2 % vs. 19 %, respectively). However, the response to G-1 was not abolished in either group, which indicates that this GPER agonist also acts on VSM.
To determine which endothelial mediators are involved in G-1-induced vascular relaxation, we examined the participation of the main relaxation pathways (NO, PGI 2 and EDHF) in the assessed response. NO modulation of G-1-induced relaxation was assessed following inhibition with L-NAME (300 μM), and the inhibition of NOS resulted in a similar attenuation of the G-1-induced vasodilatory effects in both sexes (females -F: 46.1 ± 5.4 %; males -M: 59.1 ± 4.7 %; Fig. 2A ).
The role of prostanoids was assessed in the presence of a COX inhibitor (INDO, 10 μM), and no effects on G-1-induced vasodilation were detected in either group (F: 74.2 ± 5.7 %, M: 75.2 ± 6.4 %; Fig. 2B ). To assess the participation of an endothelial mediator other than NO and PGI 2 , i.e., EDHF, the rings were concomitantly incubated with L-NAME and INDO. The combined inhibition reduced relaxation compared with the effects obtained in the absence of these inhibitors (F: 56.6 ± 5.8 %, M: 50.4 ± 5.3 %; Fig. 2C ). However, the response did not differ from that obtained with L-NAME alone, which indicates that NO is the main mediator of the response in both sexes.
To establish the mechanism involved in GPER-mediated NO production, the artery segments were incubated with LY-294,002 (2.5 μM), a PI3K-Akt pathway inhibitor. Inhibition resulted a in reduction of the G-1-induced vasodilatory response (F: 58.8 ± 2.2 %, M: 59.9 ± 1.1 %; Fig. 3 ), and these results were similar to those obtained with inhibition with L-NAME alone, which suggests that this is the main pathway involved in the GPER-mediated relaxation response.
The role of potassium channels in the vasodilatory response to G-1 was assessed through the nonspecific blockade of these channels, and in the presence of TEA (5 mM), G-1-induced relaxation was decreased in both females (54.4 ± 3.0 %) and males (59.1 ± 6.1 %) (Fig. 4) .
The selectivity of the GPER agonist was assessed in the presence of a specific GPER antagonist [G36 (1 μM)], which significantly reduced relaxation. The specificity of G-1 was also confirmed by the addition of ICI 182,780 (1 μM), which did not modify the G-1-induced relaxation in either group (data not shown).
GPER immunolocalisation
Fluorescence microscopy was performed to investigate the presence of GPER on the endothelium and VSM of the mesenteric resistance arteries from Wistar rats of both sexes. Among the females, immunolocalisation for GPER showed a greater intensity in the endothelium than in the VSM. Among the males, there was no difference in receptor fluorescence between the endothelium and VSM (Fig. 5A and B).
Discussion
The main findings of the present study are that the GPER agonist-induced relaxation of mesenteric resistance arteries did not differ as a function of sex and that the effects were partially mediated by the PI3K-Akt pathway. In addition, the potassium channels also seemed to participate in this response.
The results of the present study indicate that selective GPER activation causes relaxation of the mesenteric arteries with no differences between females and males. While Lindsey et al. [17] observed a difference in G-1-induced relaxation of the mesenteric arteries in Lewis rats as a function of sex, our data corroborate the results of previous studies that did not detect a difference in the G-1-induced response in the carotid arteries [40] and intracerebral arterioles [41] between male and female Sprague-Dawley rats. On these grounds, G-1-induced vasodilation seems to vary among species.
The effects of the selective GPER agonist on vascular reactivity in both sexes were shown to result from a balance of its actions on endothelial and VSM cells [41] , including the mesenteric arteries [42, 43] . This suggests that the GPER agonist might cause relaxation through both an endothelial-dependent mechanism and direct action on VSM.
Indeed, in our study, endothelial removal partially attenuated the G-1-induced relaxation of the mesenteric arteries in males and females, and this effect was more accentuated among the latter. This finding suggests that G-1 activation in the mesenteric arteries is partially mediated by the endothelium in both sexes, with the females being more dependent on this mechanism, as Murata et al. have also reported [41] . Accordingly, the relaxation response to G-1 was less impaired after endothelium removal in the male group, suggesting that the vascular relaxation in response to G-1 is less dependent on the presence of a functional endothelium, probably due to the similar distribution of GPER in the intima and media layers of vessels from this group, in contrast with the predominant localization of these receptors in the endothelium of the female group. The relaxation response that could still be observed in endothelium-denuded vessels can be partially attributed to the direct inhibitory action of G-1 on the mobilisation of calcium in VSM [44] , an action similar to that of oestrogen [9, 10] . The mechanisms by which G-1 acts on calcium mobilisation could be related to: (i) the type of pathway activated, such as the one comprising the epidermal growth factor receptor [45] ; (ii) the type of receptor involved, e.g. inositol triphosphate receptors or ryanodine receptors [46] or (iii) the type of calcium channel involved [47, 48] . In addition, the time of exposure (acute or chronic) to G-1 [20] and the alterations in myofilament sensitivity to [Ca 2+ ]i in the MLV could also be involved [49] . That being said, the effect of G-1 on the calcium mobilisation in VSM has not been fully elucidated.
Consistent with the functional findings, the results of the GPER immunolocalisation revealed that this receptor was present in both the endothelium and VSM of the mesenteric arteries in both sexes. Indeed, available evidence indicates that GPER is expressed in the endothelial and VSM cells of various human and animal tissues in both sexes [40, 50, 51] . In addition, GPER predominated in the endothelium of the females, while this receptor seems to be similarly distributed across the endothelial and VSM cells of males. This predominance of GPER in the endothelium of females might account for their decreased relaxation response compared with males after the endothelium was removed, which denotes the former's greater dependence on the endothelium.
Once the participation of the endothelium was established, we sought to investigate the participation of endothelial mediators (NO, PGI 2 and EDHF) in the assessed response. We found that in the presence of L-NAME, G-1-induced vasodilation was similarly attenuated in both sexes. Indeed, several studies have shown that NO participates as a mediator of relaxation after stimulation with GPER [40, 44, 52, 53] in the mesenteric arteries [42, 43] . Therefore, these findings along with ours clearly show that the vasodilatory action of GPER is at least partially associated with NO release.
Contrariwise, no involvement of other endothelial mediators in the G-1-induced response was detected. Inhibition with INDO alone did not attenuate the GPER-mediated response in either sex, which suggests that the GPER agonist may promote relaxation regardless of PGI 2 , as previously reported [43] . Similarly, the results of combined inhibition (L-NAME plus INDO) suggest that EDHF does not participate in the GPER-mediated vasodilator effects, as the action of NOS inhibition alone did not change with the concomitant inhibition of COX. Although EDHF is thought to participate in the 17 β-oestradiol-induced acute relaxation response even after being combined with NOS and COX inhibition [54, 55] , the relaxation response in our study did not change after combined inhibition, which suggests that EDHF is not a relevant mediator of G-1-induced vasodilation. Indeed, Murata et al. also detected no changes in relaxation after the used of NOS and COX inhibitors [41] . As a whole, these data indicate that GPER activation does not affect prostanoids or EDHF but that it does stimulate the NO pathway.
To identify the molecular mechanism involved in G-1-induced NO release, we inhibited the NOS activation pathway (PI3K-Akt) with LY-294,002. The results showed that the G-1-induced relaxation was attenuated in the presence of LY-294,002 in both males and females. This finding indicates that the PI3K-Akt-eNOS pathway participates in the GPER-mediated relaxation response in both sexes. Indeed, activation of the PI3K-Akt pathway through non-genomic action is associated with the phosphorylation of eNOS, resulting in NO production and release [26, 56, 57] . These data taken together strongly suggest that the NO released via G-1 induction originates in the endothelium via eNOS.
In our study, nonspecific potassium channel blockade attenuated G-1-induced vascular relaxation in both groups. The fact that 17-β-oestradiol is able to directly modulate potassium channels [58, 59] , consequently causing vascular relaxation, is well established. However, the contribution of potassium channels to the regulation of GPER-mediated vascular relaxation has been scarcely investigated, and the available data are controversial. Previous studies have shown that potassium channels play a crucial role in acute GPER-mediated relaxation involving brain microvascular endothelial cells in rats [60] , as well as the VSM of the porcine left anterior descending coronary artery [61] . Contrariwise, another study reported that participation of potassium channels in the G-1-induced response was not detected in the uterine arteries of female Sprague-Dawley rats [53] . Therefore, the participation of potassium channels in the G-1-induced response seems to vary not only among vascular beds but also as a function of the studied species. Based on our results, we suggest that G-1 is able to modulate the potassium channels in the mesenteric arteries of both sexes, as was previously demonstrated with oestrogen [62, 63] . Our data do not yet allow us to know which types of K + channels are involved in the vascular relaxation induced by G-1. The use of specific blockers could then bring new insights to the mechanism of action involved in this response.
Conclusion
The results of the present study indicate that the G-1-induced vascular relaxation of the mesenteric resistance arteries is not influenced by sex. However, the responses detected were partially dependent on the endothelium in both sexes, and such dependence seems to be greater in females, which might be accounted for by the greater intensity of GPER in the endothelium of this group. In turn, activation of the PI3K-Akt-eNOS pathway and potassium channels appears to be similar in both sexes. These findings provide a new perspective for understanding the vascular mechanisms involved in the oestrogen-mediated responses via GPER, which might contribute to the development of therapies to counteract the cardiovascular abnormalities associated with a decrease in sex hormone production.
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